We found that diltiazem treatment decreased SARS-CoV-2 infection (Fig 4E), indicating that the overexpression of ACE2 could overcome the inhibitory effect on cell binding but not the viral infection after binding. The gene discussed is ACE2; the disease is viral infectious disease.